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Abstract
Background: Different molecular alterations have been described in endometrioid endometrial
carcinoma (EECA). Among them the most frequently altered is loss of the PTEN protein, a tumor
suppressor gene. The purpose of this study was to evaluate the expression pattern of PTEN gene
in normal, hyperplastic and neoplastic endometrium.
Methods: In a study in a referral gynecologic hospital in Tehran, Iran, immunohistochemical (IHC)
evaluation of PTEN was performed on 87 consecutive specimens to the following three groups;
group A- normal proliferative endometrium(n = 29); group B- hyperplastic endometrium [including
simple hyperplasia without atypia(n = 21) and complex hyperplasia with atypia (n = 8)] and group
C- EECA(n = 29). Immunostaining of cells was analyzed by arbitrary quantitative methods according
to both slide's area staining and intensity of color reaction.
Results: PTEN immunoreactivity was present in all normal proliferative endometrium, all simple
hyperplasia, 75% of atypical complex hyperplasia and in 48% of EECA (P < 0.001). The intensity of
PTEN reaction was significantly higher in group with proliferative endometrium than hyperplastic
endometrium and EECA (P < 0.001).
Conclusion: PTEN expression was significantly higher in cyclical endometrium than in atypical
hyperplasia and endometrioid carcinoma.
Background
Endometrioid endometrial carcinoma (EECA) accounts
for three fourths of endometrial cancers and are thought
to develop following a continuum of premalignant
lesions ranging from endometrial hyperplasia without
atypia, to hyperplasia with atypia and finally to well dif-
ferentiated carcinoma[1,2]. Based on light microscopic
appearance and clinical behavior, endometrial cancers
have long been classified into major categories (type I and
II) [2-4]. Accurate diagnosis of premalignant lesions in
routine endometrial biopsies has a great clinical value in
patient management. Unfortunately several recent studies
have shown that cytological atypia which is predominant
criterion for diagnosis of premalignant lesions (atypical
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endometrial hyperplasia), have poor reproducibility
[1,3]. Therefore, solving these problems needs new
insights into the morphology of biologically defined pre-
malignant lesion of endometrium [1]. Recent molecular
diagnostic methods have provided new ancillary tools for
premalignant lesion diagnosis. EECA has a variety of
genetic alternations, including microsatellite instability
(MI) and mutations of PTEN, k-ras, and β-catenin genes
[5,6]. Also, these molecular genetic alternations have been
described in atypical endometrial hyperplasia [5]. Cur-
rently, PTEN is the most frequently altered gene in EECA
which is located on chromosome 10 [6,5]. The PTEN gene
has both lipid and protein phosphate activity and the
combination of the losses of PTEN lipid and protein phos-
phate activity can cause an aberrant cell growth and an
escape from apoptosis, as well as abnormal cell spreading
and migration [6]. Up to 50% of all EECA and 83% of
tumors with adjacent premalignant lesions show altered
PTEN, characterized by loss of expression [5-7]. Mutations
of PTEN are frequently detected in several cancers such as:
endometrium [8-13], low grade endometrioid ovarian
carcinoma (20%) that is the second most common histo-
logical subtype of ovarian cancer [14] prostate [15], breast
[16], and glial tumors [5,17,18]. Among the different his-
tological subtypes of EECA, endometrial subtypes have
the highest frequency (34-80%) of PTEN mutations [19].
PTEN - null glands (i.e., loss of PTEN expression) are
shown in a diffuse pattern in EECA but also may be
detected in morphologically normal endometrial tissue,
which suggests that PTEN alternation occur in the earliest
phase of endometrial carcinogenesis [5,17,20]. Immuno-
histochemical detection of PTEN in cycling endometrium
reveals high levels of protein expression in all different
cell types during the proliferative phase, with diminution
or absence of PTEN protein expression in mid secretory
glands [1,17,21,22]. The hypothesis that loss of PTEN
expression could be assessed by immunohistochemical
method has led to the suggestion that PTEN immunos-
taining may be a new and effective tool for screening of
malignant and premalignant endometrial lesions [11,23].
In the present study we used immunohistochemical
method to evaluate PTEN expression in three groups of
specimens from normal, hyperplastic endometrium and
EECA.
Methods
Ninety paraffin-embedded endometrial tissue samples
diagnosed as: normal proliferative endometrium consist-
ing of 14 and 16 early and late proliferative endometrium,
respectively, endometrial hyperplasia including: 22 sim-
ple hyperplasia (SH) and 8 atypical complex hyperplasia
(ACH) and 30 EECA were selected from surgical pathol-
ogy files of the department of pathology of Mirza Koochak
Khan Hospital, a referral gynecological hospital in Tehran,
Iran. Prior to data collection, the study was reviewed and
approved by the university ethical committee. All the
selected samples in the present study were curettage spec-
imens. Hematoxylin-eosin-stained sections from each
case were reviewed by an expert pathologist (NIM) to con-
firm the histological diagnosis. Hyperplasic specimens
were evaluated according to the WHO histological classi-
fication, (WHO 94) [24]. Specimens with any evidence of
chronic nonspecific endometritis, endometrial polyp,
secretory changes or progesterone effect were excluded
and the most representative paraffin block for each case
was then selected for immunohistochemical analysis.
Immunohistochemical study: Sections of 4 μm in thick-
ness were deparaffinized in xylene and rehydrated
through a series of graded alcohols. Antigen retrieval was
achieved by heat treatment at 98 centigrade's in PT mod-
ule buffer 1 (citrate buffer, PH = 6.0) for 20 minutes.
Endogenous peroxidase activity was blocked by incubat-
ing slides in serum blocking solution. The sections were
incubated with anti-PTEN polyclonal antibody (Zymed
Laboratories, South San Francisco, CA, USA) and diluted
1: 100 in phosphate buffer, for 60 minutes respectively
and then incubated in enzyme conjugate for 10 minutes.
The reaction was visualized with the Zymed immunohis-
tochemical detection kit using diaminobenzidine chro-
mogene as substrate. Finally, the sections were
counterstained with Mayer's hematoxylin. Normal pros-
tate tissue was used as positive control and the negative
control was performed without addition of the primary
antibody. Immunohistochemical slides were evaluated
synchronously by two pathologists under light micro-
scope and uniform criteria were used. Immunoreactivity
was regarded as positive when brown staining was local-
ized in the nuclei or cytoplasm of normal endometrial
glandular cell (an internal positive control) or tumoral
cell. According to Kapucuoglu et al [5] and An et al [8] the
immunoreactivity was graded arbitrarily and semi quanti-
tatively by considering the percentage and intensity of
staining on the whole section. Staining of cells was scored
as negative if < 10%, + 1 if 10%-50% and +2 if >50% of
slide's area was stained positive [25]. The intensity of
PTEN staining was scored from 0 = absent, +1 = light
brown, +2 = brown to dark brown in the nucleous or cyto-
plasm of glandular cells for each specimen.
Statistical analyses were carried out by Statistical Package
for Social Sciences v 15.0 (SPSS Inc., Chicago, IL, USA)
software for Windows using Chi-square, ANOVA and
Kruscal-Wallis tests. P value < 0.05 was considered signif-
icant.
Results
From 90 cases of the immunohistochemistry staining, 3
cases (1 case from each group: early proliferative, SH andDiagnostic Pathology 2009, 4:41 http://www.diagnosticpathology.org/content/4/1/41
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EECA) were excluded because there were no representa-
tive tissue samples after immunohistochemistry staining.
PTEN immunoreactivity was noted in all normal prolifer-
ative endometrium (29/29,100%) and SH (21/21,100%).
In ACH and EECA immunoreactivity was positive in 6 (6/
8, 75%) and 14 (14/29, 48%) cases respectively (Tables 1
and 2). The difference of immunoreactivity between the
groups were significant (P < 0.001).
PTEN immunoreactivity was heterogeneous. Some cells
within a gland or some glands were negative for PTEN
staining respectively in ACH & EECA. The normal prolif-
erative endometrium showed intense cytoplasm and/or
nucleus staining in the glandular epithelial cells (Figure
1). The lowest PTEN immunoreactivity was detected in
EECA and the differences were significant (P < 0.001). The
PTEN expression in cyclical endometrium and SH (Figure
2) was higher than in ACH and EECA (Figure 3, 4). There
was no statistically significant difference between the
PTEN expression in early and late proliferative
endometrium, SH and also between ACH and EECA.
Discussion
Endometrial carcinoma is the fifth most common cancer
of women worldwide [19].
Based on clinicophatologic observations, there are two
types of endometrial carcinoma: Type-I usually arising in
the background of endometrial hyperplasia and Type - 2
which is unrelated to estrogen [2].
Endometrial hyperplasia is classified by the WHO into
four groups, namely simple hyperplasia, simple hyperpla-
sia with atypia, complex hyperplasia, and complex hyper-
plasia with atypia. Currently, there is a lack of criteria that
could accurately predict the disease outcome and there is
need for a new classification composed of three groups:
endometrial hyperplasia (EH), endometrial intraepithe-
lial neoplasm (EIN) and endometrial carcinoma
[18,26,27]. The pathogenesis of endometrial carcinoma
and its precursor lesion is complex and involves many
molecular disturbances. The most frequently altered gene
in endometrial tumors of endometrioid histology show-
ing microsatellite instability is PTEN inactivation and sev-
eral studies have found that PTEN inactivation is
correlated with clonal growth patterns detected in
endometrial hyperplasia and carcinoma [25,28,29]. In the
present study, PTEN negative immunoreactivity was
detected in the majority of EECA and ACH but none in
typical SH and normal proliferative endometrium.
Mutter et al examined the altered PTEN expression in
endometrial tissue samples.
PTEN expression in 61% (20 of 33) of cases was com-
pletely absent and 97% (32 of 33) of cases revealed at
least some diminution in expression [11]. Allison et al
showed that biomarkers alone or in combination had
Table 1: PTEN expression based on the slide's area staining
Type of endometrium Slide Area
< 10% 10-50% >50%
Proliferative Endometrium (n)
Early 0 0 13
Late 0 0 16
Hyperplasia (n)
Simple 0 4 17
Atypical Complex 2 3 3
Carcinoma (n)
EECA 15 3 11
Table 2: PTEN expression based on the intensity of color 
reaction
Type of endometrium Color Intensity*
0+ 1 + 2
Proliferative Endometrium (n)
Early 0 1 12
Late 0 2 14
Hyperplasia (n)
Simple 0 7 14
Atypical Complex 2 3 3
Carcinoma (n)
EECA 15 8 6
*0 = absent, +1 = light brown, +2 = brown to dark brown
Immunohistochemical staining using PTEN antibody showing  strong and diffuse positivity in normal proliferative  endometrium, (PTEN, ×100) Figure 1
Immunohistochemical staining using PTEN antibody 
showing strong and diffuse positivity in normal prolif-
erative endometrium, (PTEN, ×100).Diagnostic Pathology 2009, 4:41 http://www.diagnosticpathology.org/content/4/1/41
Page 4 of 6
(page number not for citation purposes)
most consistency to make a clear distinction between nor-
mal, endometrial hyperplasia and EECA. They have con-
cluded that the combination of loss of PTEN expression
and particular histological features have got the greatest
diagnostic utility in endometrial hyperplasia [30].
In the present study, we detected loss of PTEN expression
in 52% of EECA and 25% of ACH. Orbo et al, [12]
reported loss of PTEN protein expression in 55% of spec-
imens in patients with subsequent EECA and Kapucuoglu
et al [5] found complete loss of PTEN in 20% of atypical
complex samples. The results of present study are compa-
rable to reported studies.
Except for 2 totally PTEN- negative cases of ACH, PTEN
immunoreactivity was heterogeneous in most of our
patients with ACH, in which PTEN- negative hyperplastic
glands were scattered among PTEN- positive glands.
This intermittent pattern was detected at a variety of
glands densities, ranging from the null gland with closely
packed architecture to PTEN- positive glands in the low
densities of a disordered proliferative endometrium. The
cytology of PTEN- nonexpressing glands was atypical
which different from the disordered glands. We found a
less frequent pattern of heterogeneous PTEN staining in
some benign precancer samples without cytological
changes. Based on previous studies and our experience, it
is obvious that loss of PTEN expression begins in the ear-
liest stages of endometrial tumorigenesis, under condi-
tions of excesses estrogen exposure [11]. PTEN
inactivation initiate in precancers from a normal back-
ground state, and additional PTEN damage accumulates
in the transition from premalignant to malignant disease.
In our study PTEN positivity was found in all proliferative
endometrium with no differences between early and late
proliferative phases, and the highest PTEN immunoreac-
tivity as well as homogeneity were detected in normal pro-
Immunohistochemical staining using PTEN antibody showing  strong reactivity of simple hyperplasia of endometrium,  (PTEN, ×100) Figure 2
Immunohistochemical staining using PTEN antibody 
showing strong reactivity of simple hyperplasia of 
endometrium, (PTEN, ×100).
Immunohistochemical staining using PTEN antibody showing  weak and focal reaction in atypical complex hyperplasia of  endometrium, (PTEN, ×100) Figure 3
Immunohistochemical staining using PTEN antibody 
showing weak and focal reaction in atypical complex 
hyperplasia of endometrium, (PTEN, ×100).
Immunohistochemical staining using PTEN antibody showing  complete lack of reaction in endometrioid endometrial carci- noma, (PTEN, ×100) Figure 4
Immunohistochemical staining using PTEN antibody 
showing complete lack of reaction in endometrioid 
endometrial carcinoma, (PTEN, ×100).Diagnostic Pathology 2009, 4:41 http://www.diagnosticpathology.org/content/4/1/41
Page 5 of 6
(page number not for citation purposes)
liferative endometrium. Also all cases of endometrial
hyperplasia without atypia were PTEN positive with high
immunoreactivity, but in contrast to normal proliferative
had less homogenous pattern, in which a few scattered
PTEN negative hyperplastic glands are interposed among
PTEN positive hyperplastic glands.
We found significant differences in PTEN expression
between proliferative endometrium, EECA and also
between SH and ACH.
Based on the histopathologic criteria differentiation
between EECA and ACH may be very difficult and the
reproducibility of the WHO classification in the diagnosis
of hyperplasia is disappointing [5,31].
Our results are comparable to mentioned studies, because
we found no statistically significant differences between
PTEN expressions in ACH and EECA.
Immunohistochemical identification of individual PTEN-
null glands in endometrium with excesses estrogen expo-
sure may be help to detection of precancers to an earliest
stage of malignancy. In regard to hyperplasia and atypia,
our results showed lower PTEN activity (25%) than in
other studies (55-75%); which may be due to use of poly-
clonal antibody in our study. As Pallares et al showed,
using monoclonal antibody was associated with more
acceptable results than polyclonal antibody [23].
In conclusion, decreased PTEN expression tended to asso-
ciate with malignant features of endometrium with signif-
icant statistical difference of PTEN immunoreactivity
between groups of normal endometrium, hyperplastic
changes & carcinoma. Our data suggested that loss of
PTEN expression is partly associated with the endometrial
cancers through a premalignant phase.
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